TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20215101

Group type: EXPERIMENTAL
Intervention: Search by story topic (yes)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Search by writer profile (yes)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Combination of search by story topic and writer profile
Number of subjects: 353

Group type: COMPARATOR
Intervention: No search by story topic (no)
Number of subjects: 353

Group type: COMPARATOR
Intervention: No search by writer profile (no)
Number of subjects: 353
Study: 17921395

Group type: EXPERIMENTAL
Intervention: Custards containing 20 g cooked acetylated high‐amylose maize starch (HAMSA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Custards containing 20 g cooked propionylated high‐amylose maize starch (HAMSP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Custards containing 20 g cooked butyrylated high‐amylose maize starch (HAMSB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Custards containing unacylated high‐amylose maize starch (Hylon VII, HAMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Custards containing low‐amylose maize starch (3401C, LAMS)
Number of subjects: 0
Study: 16160589

Group type: EXPERIMENTAL
Intervention: 4 mg doxazosin/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 8 mg doxazosin/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11865965

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day synthetic conjugated estrogens (n = 35)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 50
Study: 10075186

Group type: EXPERIMENTAL
Intervention: Treatment videotape
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control videotape
Number of subjects: 87
Study: 7728980

Group type: EXPERIMENTAL
Intervention: Consumption of 300 g of cooked Brussels sprouts per day for 1 week
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glucosinolate-free diet (control period)
Number of subjects: 10
Study: 1922194

Group type: EXPERIMENTAL
Intervention: Amorolfine 50 mg
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Amorolfine 100 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Clotrimazole 500 mg
Number of subjects: 118
Study: 6348177

Group type: EXPERIMENTAL
Intervention: 5 mg/kg acyclovir intravenously three times daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 37
Study: 30839416

Group type: EXPERIMENTAL
Intervention: Omidenepag isopropyl 0.002%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omidenepag isopropyl 0.0025%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30197644

Group type: EXPERIMENTAL
Intervention: Anti-human T-lymphocyte globulin (ATLG) perfusion (n = 24 kidneys)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline perfusion (Control group, n = 26 kidneys)
Number of subjects: 50
Study: 26791555

Group type: EXPERIMENTAL
Intervention: High-protein (40% energy from protein) / 3.6 carbohydrate:fat preload
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-protein (9% energy from protein) / 0.4 carbohydrate:fat preload
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-protein (40% energy from protein) / 0.4 carbohydrate:fat preload
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Carbohydrate preloads
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All preloads
Number of subjects: 36
Study: 24861583

Group type: EXPERIMENTAL
Intervention: 1 g acetazolamide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 22348447

Group type: EXPERIMENTAL
Intervention: Temporary biventricular pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pacing (atrial inhibited pacing or atrial-synchronous right ventricular pacing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 0
Study: 20652304

Group type: EXPERIMENTAL
Intervention: Combined PPC/POBH
Number of subjects: 30

Group type: COMPARATOR
Intervention: PPC and in‐the‐bag IOL implantation
Number of subjects: 30
Study: 18204148

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg/day, n=30)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Hypolipemic diet (n=28)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Untreated control (n=13)
Number of subjects: 71
Study: 16354891

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (triphasic ethinyl estradiol 35 microg + norethindrone 0.5 to 1 mg for 12 cycles of 28 days)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 183
Study: 12575340

Group type: EXPERIMENTAL
Intervention: Cataract extraction combined with IOL implantation through no-sitch small incision
Number of subjects: 93

Group type: COMPARATOR
Intervention: Cataract extraction combined with IOL implantation through conventional large incision
Number of subjects: 93
Study: 9649038

Group type: EXPERIMENTAL
Intervention: Needlescopic cholecystectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy
Number of subjects: 60
Study: 8018766

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (alpha n-1 IFN) treatment at a dosage of 3 MU/day subcutaneously for 5 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Phlebotomy alone
Number of subjects: 22
Study: 3069178

Group type: EXPERIMENTAL
Intervention: Suction drainage of axillary wounds after surgery for breast cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omission of suction drainage
Number of subjects: 0
Study: 31721277

Group type: EXPERIMENTAL
Intervention: Otaplimastat 80 mg (administered twice daily for 3 days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Otaplimastat 40 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Otaplimastat 80 mg
Number of subjects: 80
Study: 30627738

Group type: EXPERIMENTAL
Intervention: C‑MAC D‑Blade®
Number of subjects: 52

Group type: COMPARATOR
Intervention: LMA Fastrach®
Number of subjects: 52
Study: 28455423

Group type: COMPARATOR
Intervention: Care staff assessments
Number of subjects: 556
Study: 25282145

Group type: EXPERIMENTAL
Intervention: MoodSwings Plus (MS-Plus)
Number of subjects: 156

Group type: COMPARATOR
Intervention: MoodSwings (MS)
Number of subjects: 156
Study: 22398880

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Behavioral Therapy (BT)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 104
Study: 19684384

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.d.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 18556803

Group type: EXPERIMENTAL
Intervention: Right lateral position (RLP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (upright position)
Number of subjects: 60
Study: 15942770

Group type: EXPERIMENTAL
Intervention: Middle-aged group (40-50 years)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Old-aged group (60-70 years)
Number of subjects: 73
Study: 11832440

Group type: EXPERIMENTAL
Intervention: Insulin stimulation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pentagastrin stimulation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Insulin and pentagastrin
Number of subjects: 22
Study: 10412851

Group type: EXPERIMENTAL
Intervention: 500 mg amoxicillin plus 125 mg clavulanic acid (Augmentin), every 8 h for 10 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7751850

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin and aggressive management of modifiable risk factors
Number of subjects: 0
Study: 2321778

Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% bupivacaine with 5 micrograms/ml fentanyl
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10 ml of 0.25% bupivacaine with 5 micrograms/ml fentanyl plus 3.33 micrograms/ml epinephrine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lidocaine test dose
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2-chloroprocaine test dose
Number of subjects: 100
Study: 7192498

Group type: EXPERIMENTAL
Intervention: Serum antibodies to cow milk proteins
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Serum antibodies to soy protein
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cow milk and soy formulae fed from birth until 4 months of age
Number of subjects: 50
Study: 31921170

Group type: EXPERIMENTAL
Intervention: GTU®MultiHIV DNA vaccine delivered by transcutaneous (TC) and intramuscular (IM) injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30225882

Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26930159

Group type: EXPERIMENTAL
Intervention: 30 min B‐SES training at 3‐4 METs for four weeks
Number of subjects: 19
Study: 25439415

Group type: EXPERIMENTAL
Intervention: IV lidocaine 1 mg/kg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lumbar epidural lidocaine (1.5% lidocaine)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Thoracic epidural lidocaine (1.5% lidocaine)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Epidural saline (control)
Number of subjects: 66
Study: 23213984

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion group (n=26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Western medication group (n=26)
Number of subjects: 52
Study: 20371164

Group type: EXPERIMENTAL
Intervention: L-alanyl-glutamine (l-Ala-Gln)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 32
Study: 17582745

Group type: EXPERIMENTAL
Intervention: Bright light exposure
Number of subjects: 2

Group type: COMPARATOR
Intervention: Dim light exposure
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 2
Study: 15733013

Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40KD) plus ribavirin for 48 weeks
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40KD) plus ribavirin for 24 weeks
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40KD) plus ribavirin for 48 weeks in HCV genotype 1
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40KD) plus ribavirin for 24 weeks in HCV genotype 1
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40KD) plus ribavirin for 48 weeks in HCV genotypes 2 or 3
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40KD) plus ribavirin
Number of subjects: 491

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 491
Study: 12419718

Group type: EXPERIMENTAL
Intervention: Propofol sedation in elderly patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol sedation in younger patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recovery of psychomotor function in elderly patients
Number of subjects: 30
Study: 10360852

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 30
Study: 7719880

Group type: EXPERIMENTAL
Intervention: Bricanyl Turbuhaler (terbutaline sulphate 0.5 mg t.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ventolin Rotahaler (salbutamol 0.4 mg t.i.d.)
Number of subjects: 20
Study: 2126657

Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg after cord clamping
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control (no antibiotic prophylaxis)
Number of subjects: 201
Study: 7341284

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sotalol and Metoprolol (combined with thiazide diuretic)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sotalol and Metoprolol
Number of subjects: 28
Study: 31781822

Group type: EXPERIMENTAL
Intervention: Cocontraction group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Contraction group
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study: 29571566

Group type: EXPERIMENTAL
Intervention: Orange Juice (OJ)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Caffeine-free Cola
Number of subjects: 26
Study: 29029639

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at ST36 (single acupoint)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at CV12 (single acupoint)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at ST36-CV12 (matching acupoints)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25656999

Group type: EXPERIMENTAL
Intervention: Peanut sublingual immunotherapy (SLIT)
Number of subjects: 40
Study: 24724774

Group type: EXPERIMENTAL
Intervention: Whey Protein as a replacement for other sources of calories (WPR)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Whey Protein as a supplement without dietary modification (WPS)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Whey Protein with resistance exercise
Number of subjects: 626

Group type: COMPARATOR
Intervention: Whey Protein compared with carbohydrates
Number of subjects: 626

Group type: COMPARATOR
Intervention: Whey Protein compared with protein sources other than whey
Number of subjects: 626
Study: 22494623

Group type: EXPERIMENTAL
Intervention: L-BLP25
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 19397502

Group type: EXPERIMENTAL
Intervention: 10 ml 0.5% bupivacaine
Number of subjects: 29

Group type: COMPARATOR
Intervention: 10 ml 0.25% bupivacaine
Number of subjects: 29
Study: 20193521

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training at 20% of maximal intensity
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training at 60% of maximal intensity
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 60
Study: 16170977

Group type: EXPERIMENTAL
Intervention: 2.5% lidocaine/2.5% prilocaine (L/P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 20% benzocaine (Topex)
Number of subjects: 40
Study: 12240780

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg PO or IV q24h
Number of subjects: 236

Group type: COMPARATOR
Intervention: Azithromycin 500 mg IV q24h for > or = 2 days plus ceftriaxone 1 g IV q24h for 2 days
Number of subjects: 236
Study: 10422936

Group type: EXPERIMENTAL
Intervention: Neostigmine/glycopyrrolate (0.05/0.01 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 16
Study: 7818126

Group type: EXPERIMENTAL
Intervention: 4 L unhumidified O2 via nasal cannula
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: 40% oxygen by face tent
Number of subjects: 293

Group type: COMPARATOR
Intervention: Nurse‐coached lung hyperinflations
Number of subjects: 293

Group type: COMPARATOR
Intervention: No oxygen enhancing regimen
Number of subjects: 293
Study: 2204260

Group type: EXPERIMENTAL
Intervention: Trapidil 300 mg/day (TT group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (PP group)
Number of subjects: 140
Study: 728894

Group type: EXPERIMENTAL
Intervention: FAC-levamisole (LSM)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: FAC-BCG-LMS
Number of subjects: 114

Group type: COMPARATOR
Intervention: FAC chemotherapy alone
Number of subjects: 114
Study: 30113728

Group type: EXPERIMENTAL
Intervention: Outpatient consultation
Number of subjects: 314639

Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 314639
Study: 28545758

Group type: EXPERIMENTAL
Intervention: Affect Management (AM) intervention
Number of subjects: 377

Group type: COMPARATOR
Intervention: Standard skills-based HIV prevention intervention (SB)
Number of subjects: 377

Group type: COMPARATOR
Intervention: General health promotion intervention (HP)
Number of subjects: 377
Study: 25873349

Group type: EXPERIMENTAL
Intervention: Coached Care intervention visit with EMPATHy software toolkit
Number of subjects: 190

Group type: COMPARATOR
Intervention: Coached Care intervention visit without software tools
Number of subjects: 190
Study: 23424215

Group type: EXPERIMENTAL
Intervention: Caffeine at 250 mg day(-1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: DMAA at 50 mg day(-1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Caffeine at 250 mg day(-1) + DMAA at 50 mg day(-1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21376643

Group type: EXPERIMENTAL
Intervention: Heparin-bonded PTFE grafts (Hb-PTFE)
Number of subjects: 569

Group type: COMPARATOR
Intervention: PTFE grafts
Number of subjects: 569
Study: 19304089

Group type: EXPERIMENTAL
Intervention: Topical mitomycin-C (MMC) 0.2 mg/mL applied for 45 seconds after PRK
Number of subjects: 179

Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Topical mitomycin-C (MMC)
Number of subjects: 179
Study: 17526168

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methycbal (Mecolbalamin) administration
Number of subjects: 60
Study: 15225586

Group type: EXPERIMENTAL
Intervention: Blackcurrant juice (475 to 1000ml/d)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Anthocyanin drink (475 to 1000ml/d)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 57
Study: 11495222

Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 142

Group type: COMPARATOR
Intervention: Neutral mood (control)
Number of subjects: 142
Study: 10682136

Group type: EXPERIMENTAL
Intervention: Stavudine 20 mg twice daily
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg twice daily
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Stavudine (both doses)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Zidovudine (previously used)
Number of subjects: 35
Study: 8313315

Group type: EXPERIMENTAL
Intervention: FUDR (0.3 mg/kg/day) and leucovorin (30 mg/m2/day) as a 14‐day continuous infusion through an implantable hepatic arterial pump alternating with a 4‐week rest period (Group D)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: FUDR (0.25 mg/kg/day) and leucovorin (30 mg/m2/day) as a 14‐day infusion alternating with 2 weeks of saline (Group E)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: FUDR (0.3 mg/kg/day) with leucovorin (15 mg/m2/day) for 2 weeks followed by a 2‐week rest (Group F)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hepatic arterial chemotherapy with FUDR and leucovorin
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lower dose of leucovorin (15 mg/m2) with FUDR
Number of subjects: 42
Study: 3042310

Group type: EXPERIMENTAL
Intervention: BAYm 1099 (50 mg 3 times/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31556655

Group type: EXPERIMENTAL
Intervention: Transference-focused psychotherapy (TFP)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Supportive psychodynamic therapy (SPT)
Number of subjects: 82
Study: 28544774

Group type: COMPARATOR
Intervention: Hetrombopag (5 mg, 10 mg, 20 mg, 30 mg, 40 mg single dose)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hetrombopag (2.5 mg, 5.0 mg, 7.5 mg once daily for 10 days)
Number of subjects: 72
Study: 25387127

Group type: EXPERIMENTAL
Intervention: Energy Drink (ED)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All conditions (ED, PL, CTL)
Number of subjects: 19
Study: 23313564

Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Duloxetine or Placebo
Number of subjects: 168
Study: 22004303

Group type: EXPERIMENTAL
Intervention: Integrated outpatient cognitive‐behavioral intervention for co‐occurring AOD and suicidality (I‐CBT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (E‐TAU)
Number of subjects: 40
Study: 18665686

Group type: EXPERIMENTAL
Intervention: Coping and Media Literacy (CML)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Discussion as Usual (DAU)
Number of subjects: 90
Study: 15975966

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg subcutaneous injection, twice weekly for three months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: DMARDs alone (control group)
Number of subjects: 90
Study: 12883465

Group type: EXPERIMENTAL
Intervention: Liposomal ACY gel (LAG) applied five times daily for up to eight weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Plain ACY gel (PAG)
Number of subjects: 26
Study: 10856268

Group type: EXPERIMENTAL
Intervention: 10 mg omapatrilat
Number of subjects: 9

Group type: COMPARATOR
Intervention: 20 mg fosinopril
Number of subjects: 9
Study: 9379646

Group type: EXPERIMENTAL
Intervention: P III NP in patients with POAG
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: P I CP in patients with POAG
Number of subjects: 30
Study: 8409505

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 25
Study: 2428668

Group type: EXPERIMENTAL
Intervention: VBM plus 5‐fluorouracil
Number of subjects: 267

Group type: COMPARATOR
Intervention: VBM
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Synchronous chemotherapy
Number of subjects: 267

Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 267
Study: 31280100

Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (PVB)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (IV-morphine)
Number of subjects: 75
Study: 29902697

Group type: EXPERIMENTAL
Intervention: Learn to be safe with Emmy and friends™
Number of subjects: 611

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 611